Wegovy vs. Zepbound: Head-to-Head

Wegovy and Zepbound are the two FDA-approved GLP-1 medications specifically indicated for weight management. They dominate the market, the clinical trials, and the headlines. But until recently, we had no direct comparison data.

That changed with SURMOUNT-5. Here's what the numbers actually say — and what they mean for your wallet.

The Head-to-Head Data: SURMOUNT-5

Published in late 2024, SURMOUNT-5 was the first randomized, double-blind trial directly comparing Zepbound (tirzepatide 15mg) against Wegovy (semaglutide 2.4mg) for weight loss over 72 weeks.

Metric	Wegovy (Semaglutide)	Zepbound (Tirzepatide)
Avg. body weight loss	13.7%	20.2% ✓
On a 220 lb person	~30 lbs	~44 lbs ✓
Patients losing ≥15%	~43%	~72% ✓
Patients losing ≥20%	~23%	~55% ✓
GI side effects	Similar rates	Similar rates
Discontinuation rate	Comparable	Comparable

The difference is clinically meaningful. Zepbound's dual GLP-1/GIP mechanism appears to provide a genuine advantage in total weight loss and in the percentage of patients reaching significant milestones.

The Price Comparison

Raw efficacy is only half the story. Most people choose their GLP-1 based on what they can actually afford.

Pricing Pathway	Wegovy	Zepbound
Retail list price	$1,349/mo	$1,086/mo
Manufacturer self-pay	$349/mo (NovoCare) ✓	$399/mo (LillyDirect)
Oral option	$149/mo (pill) ✓	Not available
Vial option (self-inject)	Not available	$299/mo (LillyDirect) ✓
Insurance coverage	Broader (CVD indication) ✓	Narrower (weight only)
Medicare pathway	Yes (via CVD indication) ✓	Limited
Savings card (commercial ins.)	As low as $0 copay	As low as $0 copay

How They Work Differently

Wegovy (Semaglutide 2.4mg)

Semaglutide is a GLP-1 receptor agonist only. It mimics the GLP-1 hormone that signals satiety after eating, slows gastric emptying, and reduces appetite. It's been on the market since 2021 (as Wegovy) and has the longest safety track record of any dedicated weight loss GLP-1.

In February 2025, the FDA expanded Wegovy's label to include cardiovascular risk reduction — a landmark decision that opened insurance and Medicare pathways that Zepbound can't access.

Zepbound (Tirzepatide 15mg)

Tirzepatide is a dual GLP-1 and GIP receptor agonist. It activates two gut hormones instead of one, which appears to produce greater metabolic effects. FDA-approved for weight management since late 2023, Zepbound has also been approved for obstructive sleep apnea.

Eli Lilly is pursuing a cardiovascular outcomes trial (SURPASS-CVOT), but results aren't expected until 2027. Until then, Zepbound lacks the CV indication that gives Wegovy its insurance advantage.

Side Effect Comparison

Both medications share similar gastrointestinal side effects, which are the most common reason people discontinue treatment:

Side Effect	Wegovy	Zepbound
Nausea	~40-44%	~24-33%
Diarrhea	~30%	~18-25%
Vomiting	~24%	~10-13%
Constipation	~24%	~17-23%
Injection site reactions	Mild	Mild

SURMOUNT-5 reported comparable tolerability between the two drugs, with no new safety signals for either. Both carry black box warnings about thyroid C-cell tumors (observed in rodents) and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma.

Who Should Choose Wegovy

You have insurance that covers it. Wegovy's cardiovascular indication makes it far easier to get covered by commercial insurance and even some Medicare plans. If your insurer will pay, your out-of-pocket could be under $50/month with a savings card.

You want the oral option. Oral Wegovy at $149/month is the most affordable brand-name GLP-1 available — no injections required.

You want the longest safety record. Semaglutide has been in clinical use since 2017 (as Ozempic) with millions of patient-years of real-world data.

Budget is the primary concern. Between NovoCare pricing, the oral pill, and broader insurance coverage, Wegovy simply has more affordable pathways.

Who Should Choose Zepbound

Maximum weight loss is the priority. If you want to lose the most weight possible, the SURMOUNT-5 data is clear — tirzepatide produces roughly 47% more weight loss than semaglutide.

You have sleep apnea. Zepbound is the only GLP-1 with an FDA indication for obstructive sleep apnea, which may help with insurance coverage if you have that diagnosis.

You prefer the vial option. LillyDirect offers Zepbound in single-dose vials at $299/month — less expensive than the auto-injector pen and a good option for people comfortable with self-injection.

You can afford the self-pay price. Without insurance, Zepbound via LillyDirect ($299-399/month) is competitive, though Wegovy's oral pill still undercuts it.

The Compounded Alternative

If brand-name pricing for either drug is still out of reach, compounded versions of both semaglutide and tirzepatide are available through licensed telehealth platforms at significantly lower prices — typically $146-350/month depending on the provider and dosage.

Compounded medications are not FDA-approved products. They're prepared by licensed compounding pharmacies under FDA enforcement discretion. The regulatory landscape is complex and evolving — check our compounded semaglutide vs. tirzepatide comparison for full details.

Our Bottom Line

Both medications are effective. Both are safe. The choice comes down to your specific situation:

If you...	Choose
Want maximum weight loss above all	Zepbound
Need the most affordable brand-name option	Wegovy (oral, $149/mo)
Have insurance that covers GLP-1s	Wegovy (easier to get covered)
Have sleep apnea	Zepbound (FDA indication)
Want self-inject vials	Zepbound ($299/mo)
Are on Medicare	Wegovy (CV indication pathway)
Prefer the longest safety track record	Wegovy

There is no wrong choice between these two medications. The wrong choice is waiting because you can't decide.